Pharma companies – the big R&D spenders

This question can be analyzed an-infinitum but the real answer is simple. Each of the Pharma companies here grows by their ability to research new drugs and chemical compounds. The more they spend on research, the better they will perform moving forward. The chart below is a percentage of what these companies spend on R&D…

Fortune highlighted Regeneron for its ability to do drug discovery for much less. To quote from their article here are the costs for drug development by some of the Big Pharma: Merck : $5.5 Billion per drug Pfizer: $7.8 Billion Sanofi: $10 Billion Average for other Pharma: $4.3 Billion Regeneron: $0.75 Billion There may be…

Nearly 100 cancer physicians had published a report in Blood that the prices of drugs for cancer that typically cost about $100,000 per year are unsustainable and something needs to be done to manage that for the patients. The article is worth a read and compares a UK study which typically puts as a life…

Tufts Center for the Study of Drug Development does research on drug development and publishes regular reports on drug development. The reports are primarily research conducting by the Center on the current trends in drug development, meetings, forums, courses and discussions. They do not come up with novel methods for drug development but rather act…

FDA just accepted an IND from Voyageur therapeutics for Parkinson’s disease. This trial essentially adds a gene for an enzyme that Aromatic L Amino acid Decarboxylase (AADC) that catalyzes the conversion of levodopa to dopamine. This is added to the putamen (brain) and adds the adeno associated virus that would carry the gene. It is…